SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is trending as traders speculate on its potential for significant price appreciation, drawing comparisons to Zcash and citing its privacy-focused features, scarce supply, and potential to close the valuation gap with other privacy-oriented coins. While many investors are optimistic about a "super spike" or breakout, others express frustration with the recent downward price action and characterize the asset as highly volatile.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin Trust ETF

IBIT is currently trending as investors monitor increased institutional capital inflows and the potential impact of the proposed crypto Clarity Act. The community sentiment remains divided, with some traders citing signs of a technical bottom and bullish accumulation while others express skepticism over price volatility and macro headwinds.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs is experiencing heightened volatility as traders weigh recent earnings performance against broader sector trends, with significant debate surrounding its valuation and potential for inclusion in major market indices.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is trending as investors debate ongoing buyout speculation, the company's strategic pivot away from internal discovery to an external innovation model, and the potential impact of future pipeline readouts. Community sentiment remains divided between frustration over historical price performance and optimism regarding the long-term value of its HAE franchise.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It operates through the following segments: Uranium, Rare Earth Elements (REE), and Heavy Mineral Sands (HMS). The uranium segment engages in conventional and ISR uranium extraction, recovery and sales of uranium from mineral properties and the recycling of uranium-bearing materials generated by third parties along with the exploration, permitting and evaluation of uranium properties in the U.S. The REE segment is engaged in the company’s initiatives to progress towards full REE separation capabilities at the Mill to produce both light and heavy separated REE oxides in the coming years. The HMS segment engages in the exploration, development and recovery of HMS at the Kwale Project, Bahia Project, Vara Mada Project and the company’s equity method investments in the Donald Project JV and Tate. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is trending as investors focus on its strategic transformation into a vertically integrated critical minerals supplier, particularly its move to develop domestic mine-to-magnet capabilities to support U.S. national security and satisfy upcoming defense supply chain requirements. Sentiment is mixed, with some traders expressing frustration over recent price volatility and sector-wide macro headwinds, while long-term investors highlight the company's alignment with government policy and the recent expansion of its heavy rare earth production capacity.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing increased volatility and trading volume following its listing on the Upbit exchange. Community sentiment remains sharply divided between traders viewing the spike as an opportunity for gains and those labeling the price action a typical pump-and-dump cycle.

Robinhood GLD is a tokenized representation of SPDR Gold Shares (GLD) common stock, issued on Robinhood Chain, Robinhood's own blockchain built to bring tokenized real-world assets on-chain. Each token is designed to track the price of the underlying GLD share, giving holders on-chain price exposure to SPDR Gold Shares's stock. The token is freely transferable and composable across the Robinhood Chain ecosystem. It's part of Robinhood's broader initiative to expand access to tokenized U.S. equities via blockchain technology, alongside a wider lineup of tokenized stock tokens launching on the same network.

GoldCoin

GoldCoin is experiencing heightened interest as traders frequently compare it to other assets like gold and crypto, while discussing technical trading strategies and volatility surrounding recent economic data.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunrun is trending following a partnership announcement with Tesla and Renew Home to create a virtual power plant designed to supply energy to AI data centers, though the stock has faced volatility and selling pressure as traders debate the significance of the news versus long-term debt and interest-rate concerns. While some investors view the deal as a major catalyst for future growth and a potential short squeeze, others remain skeptical, citing a history of price pullbacks following positive headlines and broader sector weakness.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Investors are emphasizing the ETF's role as a defensive "foundation" and income-generating cornerstone within portfolios, favoring its focus on high-quality, dividend-growth companies during periods of tech sector volatility. Community discussion highlights a sustained preference for dollar-cost averaging into the fund to capture long-term compounding benefits despite recent price gains.

Silence Therapeutics Plc engages in the discovery, delivery, and development of ribonucleic acid (RNA) therapeutics. It also develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.

Silence Therapeutics Plc - ADR

Silence Therapeutics is trending following the pricing of an upsized $175 million public offering and positive Phase 2 clinical trial results for its polycythemia vera candidate, divesiran. While some investors remain cautious about potential dilution and competitive pressures, others view the data as best-in-class and see significant upside potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know 

Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?

The consensus price target hints at a 31.5% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Castle Biosciences to Participate in Upcoming Investor Conferences

Castle Biosciences to Participate in Upcoming Investor Conferences Castle Biosciences to Participate in Upcoming Investor Conferences PR Newswire FRIENDSWOOD, Texas, Aug. 20, 2026 FRIENDSWOOD, Texas, Aug. 20, 2026 /PRNewswire/ -- Castle Biosciences, Inc.(Nasdaq: CSTL), a company improving health...

Castle Biosciences Approved for Dual Listing on Nasdaq Texas

Castle Biosciences Approved for Dual Listing on Nasdaq Texas Castle Biosciences Approved for Dual Listing on Nasdaq Texas PR Newswire FRIENDSWOOD, Texas, Aug. 17, 2026 FRIENDSWOOD, Texas, Aug. 17, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through...

Castle Biosciences (CSTL) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates

Castle Biosciences (CSTL) delivered earnings and revenue surprises of +84.09% and +18.61%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Castle Biosciences Reports Second Quarter 2026 Results

Castle Biosciences Reports Second Quarter 2026 Results Castle Biosciences Reports Second Quarter 2026 Results PR Newswire FRIENDSWOOD, Texas, July 30, 2026 Delivered Q2 2026 revenue of $103.5 millionQ2 2026 total test reports for our core revenue drivers (DecisionDx-Melanoma, TissueCypher...

Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference

Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference PR Newswire FRIENDSWOOD, Texas, July 22, 2026 FRIENDSWOOD, Texas, July 22, 2026 /PRNewswire/ -- Castle Biosciences, Inc.(Nasdaq...

Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx Test

Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx Test Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx Test PR Newswire FRIENDSWOOD, Texas, July 14, 2026 Approval expands access to Castle's precision medicine...

Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026

Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 PR Newswire FRIENDSWOOD, Texas, July 9, 2026 FRIENDSWOOD, Texas, July 9...

Castle Biosciences, Inc. is a molecular diagnostics company, which offers innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Castle Biosciences Inc

Neutral Sentiment

The Federal Reserve hasn't raised rates at all in 2026, but hawkish comments from Fed Chair Kevin Warsh at the Jackson Hole symposium have pushed September rate hike odds as high as 66%, a sharp jump from under 40% just a week earlier. How many rate hikes do you expect from the Fed in 2026? Vote and explain your reasoning in the comments.

How many rate hikes do you expect from the Fed in 2026?

Feed

News

Sentiment

Earnings

Fundamentals

Info

CSTL News